Skip to main content
NCD 190.17 · version 1 · Laboratory NCD

NCD 190.17: Prothrombin Time (PT)

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.17

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
7,273 covered ICD-10
233 non-covered

TL;DR

NCD 190.17 sets Medicare's national policy for prothrombin time (pt) under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • A PT may be used to assess patients taking warfarin. The prothrombin time is generally not useful in monitoring patients receiving heparin who are not taking warfarin. As a laboratory NCD it carries a national ICD-10 edit list: 7,273 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

Basic plasma coagulation function is readily assessed with a few simple laboratory tests: the partial thromboplastin time (PTT), PT, thrombin time (TT), or a quantitative fibrinogen determination. The PT test is one in-vitro laboratory test used to assess coagulation. While the PTT assesses the intrinsic limb of the coagulation system, the PT assesses the extrinsic or tissue factor dependent pathway. Both tests also evaluate the common coagulation pathway involving all the reactions that occur after the activation of factor X.

Extrinsic pathway factors are produced in the liver and their production is dependent on adequate vitamin K activity. Deficiencies of factors may be related to decreased production or increased consumption of coagulation factors. The PT/INR is most commonly used to measure the effect of warfarin and regulate its dosing. Warfarin blocks the effect of vitamin K on hepatic production of extrinsic pathway factors.

A PT is expressed in seconds and/or as an international normalized ratio (INR). The INR is the PT ratio that would result if the WHO reference thromboplastin had been used in performing the test.

Current medical information does not clarify the role of laboratory PT testing in patients who are self monitoring. Therefore, the indications for testing apply regardless of whether or not the patient is also PT self-testing.

Indications and limitations of coverage

Indications

• A PT may be used to assess patients taking warfarin. The prothrombin time is generally not useful in monitoring patients receiving heparin who are not taking warfarin.

• A PT may be used to assess patients with signs or symptoms of abnormal bleeding or thrombosis. For example: swollen extremity with or without prior trauma; unexplained bruising; abnormal bleeding, hemorrhage or hematoma; petechiae or other signs of thrombocytopenia that could be due to disseminated intravascular coagulation.

• A PT may be useful in evaluating patients who have a history of a condition known to be associated with the risk of bleeding or thrombosis that is related to the extrinsic coagulation pathway. Such abnormalities may be genetic or acquired. For example: dysfibrinogenemia; afibrinogenemia (complete); acute or chronic liver dysfunction or failure, including Wilson's disease and Hemochromatosis; disseminated intravascular coagulation (DIC); congenital and acquired deficiencies of factors II, V, VII, X; vitamin K deficiency; lupus erythematosus; hypercoagulable state; paraproteinemia; lymphoma; amyloidosis; acute and chronic leukemias; plasma cell dyscrasia; HIV infection; malignant neoplasms; hemorrhagic fever; salicylate poisoning; obstructive jaundice; intestinal fistula; malabsorption syndrome; colitis; chronic diarrhea; presence of peripheral venous or arterial thrombosis or pulmonary emboli or myocardial infarction; patients with bleeding or clotting tendencies; organ transplantation; presence of circulating coagulation inhibitors.

• A PT may be used to assess the risk of hemorrhage or thrombosis in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis. For example: evaluation prior to invasive procedures or operations of patients with personal history of bleeding or a condition associated with coagulopathy prior to the use of thrombolytic medication.

Limitations

• When an ESRD patient is tested for PT, testing more frequently than weekly requires documentation of medical necessity, e.g., other than chronic renal failure or renal failure, unspecified.

• The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of warfarin. In a patient on stable warfarin therapy, it is ordinarily not necessary to repeat testing more than every two to three weeks. When testing is performed to evaluate a patient with signs or symptoms of abnormal bleeding or thrombosis and the initial test result is normal, it is ordinarily not necessary to repeat testing unless there is a change in the patient's medical status.

• Since the INR is a calculation, it will not be paid in addition to the PT when expressed in seconds, and is considered part of the conventional PT test.

• Testing prior to any medical intervention associated with a risk of bleeding and thrombosis (other than thrombolytic therapy) will generally be considered medically necessary only where there are signs or symptoms of a bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis or a condition associated with a coagulopathy. Hospital/clinic-specific policies, protocols, etc., in and of themselves, cannot alone justify coverage.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.17 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 7,273 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.17
CodeCode set
85610CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $4.29, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.17 edits, October 2026
CodeCLFS amountWith QWPricing
85610$4.29$4.29national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 7,273 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.17 (sample)
ICD-10-CMDescriptionEffective
A01.00Typhoid fever, unspecified2015-10-01
A01.01Typhoid meningitis2015-10-01
A01.02Typhoid fever with heart involvement2015-10-01
A01.03Typhoid pneumonia2015-10-01
A01.04Typhoid arthritis2015-10-01
A01.05Typhoid osteomyelitis2015-10-01
A01.09Typhoid fever with other complications2015-10-01
A01.1Paratyphoid fever A2015-10-01
A01.2Paratyphoid fever B2015-10-01
A01.3Paratyphoid fever C2015-10-01
A01.4Paratyphoid fever, unspecified2015-10-01
A02.0Salmonella enteritis2015-10-01
A02.1Salmonella sepsis2015-10-01
A02.20Localized salmonella infection, unspecified2015-10-01
A02.21Salmonella meningitis2015-10-01
A02.22Salmonella pneumonia2015-10-01
A02.23Salmonella arthritis2015-10-01
A02.24Salmonella osteomyelitis2015-10-01
A02.25Salmonella pyelonephritis2015-10-01
A02.29Salmonella with other localized infection2015-10-01
A02.8Other specified salmonella infections2015-10-01
A02.9Salmonella infection, unspecified2015-10-01
A18.84Tuberculosis of heart2015-10-01
A41.9Sepsis, unspecified organism2015-10-01
A91Dengue hemorrhagic fever2015-10-01
A92.0Chikungunya virus disease2015-10-01
A95.0Sylvatic yellow fever2015-10-01
A95.1Urban yellow fever2015-10-01
A95.9Yellow fever, unspecified2015-10-01
A96.0Junin hemorrhagic fever2015-10-01
A96.1Machupo hemorrhagic fever2015-10-01
A96.8Other arenaviral hemorrhagic fevers2015-10-01
A96.9Arenaviral hemorrhagic fever, unspecified2015-10-01
A98.0Crimean-Congo hemorrhagic fever2015-10-01
A98.1Omsk hemorrhagic fever2015-10-01
A98.2Kyasanur Forest disease2015-10-01
A98.5Hemorrhagic fever with renal syndrome2015-10-01
A98.8Other specified viral hemorrhagic fevers2015-10-01
A99Unspecified viral hemorrhagic fever2015-10-01
B15.0Hepatitis A with hepatic coma2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.17 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 10 codes added and 8 codes removed against January 2026. CMS marked 10 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.

ICD-10-CM codes added to NCD 190.17 in October 2026
ICD-10-CMFY2027 descriptionResult
D69.11Glanzmann thrombastheniacovered
D69.19Other qualitative platelet defectscovered
I42.00Dilated cardiomyopathy, unspecifiedcovered
I42.01Familial-genetic dilated cardiomyopathycovered
I42.09Other dilated cardiomyopathycovered
I42.81Arrhythmogenic cardiomyopathycovered
I42.89Other cardiomyopathies not elsewhere classifiedcovered
I49.81Brugada syndromecovered
I49.82Ventricular bigeminycovered
I49.89Other specified cardiac arrhythmias not elsewhere classifiedcovered
ICD-10-CM codes removed from NCD 190.17 in October 2026
ICD-10-CMDescriptionWasWhy
D69.1Qualitative platelet defectscovereddeleted from ICD-10-CM; replaced by D69.11, D69.19
I42.0Dilated cardiomyopathycovereddeleted from ICD-10-CM; replaced by I42.00, I42.01, I42.09
I42.8Other cardiomyopathiescovereddeleted from ICD-10-CM; replaced by I42.81, I42.89
I49.8Other specified cardiac arrhythmiascovereddeleted from ICD-10-CM; replaced by G90.A, I49.81, I49.82, I49.89
T52.8X1AToxic effect of other organic solvents, accidental (unintentional), initial encountercovereddeleted from ICD-10-CM; replaced by T52.811A, T52.821A, T52.891A
T52.8X2AToxic effect of other organic solvents, intentional self-harm, initial encountercovereddeleted from ICD-10-CM; replaced by T52.812A, T52.822A, T52.892A
T52.8X3AToxic effect of other organic solvents, assault, initial encountercovereddeleted from ICD-10-CM; replaced by T52.813A, T52.823A, T52.893A
T52.8X4AToxic effect of other organic solvents, undetermined, initial encountercovereddeleted from ICD-10-CM; replaced by T52.814A, T52.824A, T52.894A

Codes on this NCD's list by release: October 2025: 7,469 · January 2026: 7,504 · October 2026: 7,506. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.17

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.17

What does NCD 190.17 cover?

• A PT may be used to assess patients taking warfarin. The prothrombin time is generally not useful in monitoring patients receiving heparin who are not taking warfarin. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.17 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.17?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.17?

The October 2026 laboratory NCD edit list contains 7,273 ICD-10-CM codes that support prothrombin time (pt) (for example A01.00 Typhoid fever, unspecified; A01.01 Typhoid meningitis; A01.02 Typhoid fever with heart involvement) and 233 codes that deny. The list applies to 85610.

How often does the lab NCD code list for 190.17 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.